Efficacy of Trifluridine Tipiracil Tablets (Lonsurf)

Trifluridine and tipiracil tablets (Lonsurf) prolonged overall survival in patients with metastatic colorectal cancer (HCC) and metastatic gastric cancer, in clinical studies in which all patients had previously received other treatments. In a major study involving 800 patients, patients who received trifluridine and tipiracil lived an average of 7.1 months. In another major study involving 492 patients, patients who received trifluridine and bevacizumab lived an average of 10.8 months, while those who received only trifluridine lived an average of 7.5 months. In a study involving 507 adults with metastatic gastric cancer, patients treated with trifluridine and tipiracil lived an average of 5.7 months.